MEDICINA
Departamento
Università de Roma La Sapienza
Roma, ItaliaPublicaciones en colaboración con investigadores/as de Università de Roma La Sapienza (20)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia
Haematologica, Vol. 109, Núm. 2, pp. 521-532
2022
-
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414
2021
-
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network
HemaSphere
-
Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 6
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2019
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973
-
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106
-
The Big Data Sjögren consortium: A project for a new data science era
Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23
2018
-
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)
Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111
2017
-
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367
2016
-
Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis
Psychiatry Research, Vol. 238, pp. 270-276
2015
-
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
Leukemia Research, Vol. 39, Núm. 3, pp. 296-306
2014
-
Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death
Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180
2013
-
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
Journal of Clinical Oncology, Vol. 31, Núm. 4, pp. 448-455
2011
-
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial
British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221
-
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma
European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384
2008
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917
-
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Haematologica, Vol. 93, Núm. 3, pp. 431-438
2006
-
Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia
Leukemia, Vol. 20, Núm. 1, pp. 48-54